A landmark study shows millions of women with breast cancer could skip chemotherapy thanks to a genomic test that determines who needs the treatment and who doesn’t.
The randomised international trial specifically looked at whether the test could identify those patients who would not benefit from chemotherapy, and then see if they could safely avoid it.
